Aims: To assess the effect of loratadine in exercise induced asthma. Methods: Randomised, double blind, placebo controlled study of 10 mg oral loratadine, once daily for three days in 11 children. At the end of the treatment period FEV 1 was measured, and patients were exercised on a treadmill. FEV 1 measurements were repeated at intervals after exercise. Results: Loratadine significantly reduced the decrease in FEV 1 after exercise at two, five, 10, 15, and 30 minutes, compared with placebo (p < 0.05). However, the mean decrease in FEV 1 at five minutes was more than 15% of baseline in the loratadine group. Conclusions: Loratadine reduces, but does not prevent, exercise induced asthma in children. E xercise induced asthma (EIA) is defined as a reduction of 15% or more in forced expiratory volume in one second (FEV 1 ) after exercise, and is known to occur in 70-80% of asthmatic children.
1Loratadine is a long acting, highly selective histamine H 1 receptor antagonist, and possesses some anti-inflammatory activity. Loratadine is protective against histamine induced bronchoconstriction, and inhibits allergen induced early and late phase airway obstruction in asthmatics. Recent studies have shown that loratadine produces a mild bronchodilatation, and is effective in the long term treatment of allergic asthma. 2 We investigated the effect of a 10 mg oral dose of loratadine, once daily for three days, on EIA in children, as we are unaware of any studies of its effects on EIA in the paediatric population.
METHODSFourteen children (eight boys, six girls; mean age 11.45 (SE 0.87) years, range 7-17) with bronchial asthma, diagnosed within the past month, were studied. All patients were judged atopic on the basis of positive skin tests to common allergens other than pollens, and increased serum concentrations of total and specific IgE. All patients had a history of exercise induced asthma, and had been previously shown to develop airway obstruction after exercise on a treadmill. To avoid the probable influences of seasonal allergies, patients with pollen allergies were excluded. Patients were excluded if they had symptoms or physical signs suggestive of renal, hepatic, or cardiovascular disease.The lung function entry criterion on the exercise test days was an FEV 1 above 75% of predicted. During the study period, the patients had no medical condition that was likely to interfere with the evaluation of the clinical response to medication. None had a history of intolerance to antihistamines. Patients were symptom free as a result of the use of inhaled corticosteroids (budesonide 200 µg twice daily in seven, fluticasone propionate 125 µg twice daily in seven) with a baseline FEV 1 above 85% (SE 3.4%) of predicted normal. The inhaled corticosteroids were discontinued one week before the study period and no medication other than short acting β 2 adrenergic agonists was allowed during the trial. No patients had taken oral steroids or antihistamines in the past three months. None were using cromolyn sodium, long acting β 2 adr...